Affimed to Present at Upcoming Investor Conferences

11/9/2021, 12:30 PM (Source: GlobeNewswire)

HEIDELBERG, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following investor conferences during the month of November 2021.

Stifel 2021 Virtual Healthcare Conference (November 15 - 17, 2021)
Date: Monday, November 15, 2021
Presentation Time: 8:00 a.m. EST
Location: Virtual

Jefferies London Healthcare Conference 2021 (November 16 - 19, 2021)
Date: Friday, November 19, 2021
Presentation Time: The Fireside Chat will become available on November 18 at 3:00 a.m. EST
Location: Virtual

For more information on the conferences or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at or phone at +1 (917) 436-8102.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit:

Affimed Investor Contact
Alexander Fudukidis
Director, Head of Investor Relations
Tel.: +1 (917) 436-8102

Primary Logo

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.